down arrow

Carna Biosciences, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: JP3220550002
  • TKS: 4572
JPY
449.00
0.00 (0.00%)

Sep 18

TKS

 View all stocks in this country
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Cyfuse Biomedical KK
Peptidream, Inc.
Oncolys BioPharma, Inc.
OncoTherapy Science, Inc.
GNI Group Ltd.
Carna Biosciences, Inc.
MEDINET Co., Ltd.
Chiome Bioscience, Inc.
StemCell Institute
SUSMED, Inc.
Stella Pharma Corp.

Why is Carna Biosciences, Inc. ?

1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
  • Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -358.28
2
Risky -
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of 103.17%, its profits have risen by 2.3%
stock-recommendationReal-Time Research Report

Verdict Report

How much should you sell?

  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Carna Biosciences, Inc. for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
Carna Biosciences, Inc.
103.17%
24.38
92.82%
Japan Nikkei 225
43.52%
1.48
29.43%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
-9.67%
EBIT Growth (5y)
-22.52%
EBIT to Interest (avg)
-327.05
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.77
Sales to Capital Employed (avg)
0.40
Tax Ratio
0.13%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-42.45
EV to EBIT
-3.75
EV to EBITDA
-3.75
EV to Capital Employed
14.18
EV to Sales
12.34
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-377.80%
ROE (Latest)
Negative BV
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

21What is working for the Company
NET PROFIT(HY)

Higher at JPY -1,007.29 MM

NET SALES(Q)

Highest at JPY 217.52 MM

OPERATING PROFIT MARGIN(Q)

Highest at -227.88 %

RAW MATERIAL COST(Y)

Fallen by -8.13% (YoY

DEBT-EQUITY RATIO (HY)

Lowest at -217.19 %

INVENTORY TURNOVER RATIO(HY)

Highest at 1.42 times

EPS(Q)

Highest at JPY -26.34

-13What is not working for the Company
ROCE(HY)

Lowest at -438.37%

INTEREST(Q)

At JPY 21.03 MM has Grown at 59.51%

CASH AND EQV(HY)

Lowest at JPY 2,583.96 MM

Here's what is working for Carna Biosciences, Inc.

Net Sales
Highest at JPY 217.52 MM and Grown
In each period in the last five periods
MOJO Watch
Near term sales trend is very positive

Net Sales (JPY MM)

Net Sales
At JPY 217.52 MM has Grown at 40.48%
over average net sales of the previous four periods of JPY 154.84 MM
MOJO Watch
Near term sales trend is very positive

Net Sales (JPY MM)

Operating Profit Margin
Highest at -227.88 % and Grown
In each period in the last five periods
MOJO Watch
Company's profit margin has improved

Operating Profit to Sales

Net Profit
Higher at JPY -1,007.29 MM
than preceding 12 month period ended Jun 2026
MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (JPY MM)

EPS
Highest at JPY -26.34
in the last five periods
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (JPY)

Debt-Equity Ratio
Lowest at -217.19 %
in the last five Semi-Annual periods
MOJO Watch
The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Inventory Turnover Ratio
Highest at 1.42 times
in the last five Semi-Annual periods
MOJO Watch
Company has been able to sell its inventory faster

Inventory Turnover Ratio

Raw Material Cost
Fallen by -8.13% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Carna Biosciences, Inc.

Interest
At JPY 21.03 MM has Grown at 59.51%
period on period (QoQ)
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (JPY MM)

Cash and Eqv
Lowest at JPY 2,583.96 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is deteriorating

Cash and Cash Equivalents

Footer loading